Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) – Research analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Atossa Genetics in a research report issued on Friday, May 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.16) for the quarter, up from their prior estimate of ($1.45). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.58) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q3 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($0.49) EPS, FY2028 earnings at ($0.31) EPS, FY2029 earnings at ($0.15) EPS and FY2030 earnings at ($0.09) EPS.
Atossa Genetics (NASDAQ:ATOS – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12).
Get Our Latest Stock Report on ATOS
Atossa Genetics Stock Performance
Shares of ATOS stock opened at $5.16 on Wednesday. The stock’s fifty day moving average is $5.25 and its two-hundred day moving average is $8.09. The firm has a market capitalization of $44.43 million, a P/E ratio of -1.81 and a beta of 1.25. Atossa Genetics has a fifty-two week low of $3.76 and a fifty-two week high of $19.35.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ATOS. &PARTNERS purchased a new position in shares of Atossa Genetics during the 4th quarter worth $25,000. Hudson Bay Capital Management LP purchased a new position in shares of Atossa Genetics during the 2nd quarter worth $26,000. Gallagher Capital Advisors LLC purchased a new position in shares of Atossa Genetics during the 3rd quarter worth $27,000. JPMorgan Chase & Co. raised its holdings in shares of Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after acquiring an additional 35,474 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after acquiring an additional 35,629 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.
About Atossa Genetics
Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.
The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.
Further Reading
- Five stocks we like better than Atossa Genetics
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
